Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723863 | 0.93 | EGLN1 (0.50) | EGLN1TDP1EPHX1ALOX15GAA | |
| SCHEMBL20827071 | 0.93 | EPHX1 (0.50) | EGLN1TDP1EPHX1ALOX15ALDH1A1 | |
| SCHEMBL24710101 | 0.87 | EGLN1 (0.45) | EGLN1TDP1ALOX15GAAALDH1A1 | |
| SCHEMBL14820354 | 0.82 | EGLN1 (0.44) | EGLN1GAAMAPT | |
| SCHEMBL8392106 | 0.80 | TDP1 (0.48) | TDP1EPHX1GAAALDH1A1MEN1 | |
| SCHEMBL13387503 | 0.80 | TDP1 (0.48) | TDP1EPHX1GAAALDH1A1MEN1 | |
| SCHEMBL14805893 | 0.77 | EGLN1 (0.40) | EGLN1GAAALDH1A1MEN1KMT2A | |
| SCHEMBL24170016 | 0.76 | CYP2D6 (0.46) | EGLN1TDP1EPHX1GAAALDH1A1 | |
| SCHEMBL20827053 | 0.75 | EGLN1 (0.47) | EGLN1EPHX1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15154092 | 0.75 | EGLN1 (0.44) | EGLN1GAAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914273-B | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | ELI LILLY AND COMPANY (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| EP-3665174-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | Eli Lilly and Company (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914273-A | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019032383-A1 | [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | PDE3B, PDE3A, PDE5A | EGLN1 1240/4885TDP1 167/4885EPHX1 1176/4885 |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | PDE3B, PDE3A, PDE5A | EGLN1 1240/4885TDP1 167/4885EPHX1 1176/4885 |
| US-20180099973-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EGLN1 239/4885TDP1 696/4885EPHX1 681/4885 |
| US-20170233396-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EGLN1 239/4885TDP1 696/4885EPHX1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.